Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share… Dec 15, 2021
After 283 Days, Health Minister (Finally) Grants Psilocybin Exemptions To Three Canadians With Mental Health Conditions Dec 14, 2021
Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as Independent… Dec 14, 2021
atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated… Dec 14, 2021
